Inactive Instrument

PCAS Stock

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

As early as today, start finding the best investment opportunities!

24-02-09	Orapi: takeover bid reopens on February 12
24-02-02	Orapi: 3.15 million shares tendered to the takeover bid
23-12-22	Orapi: takeover bid opens on December 27
23-12-18	PCAS: 200 ME capital increase
23-11-03	PCAS: OPAS to start this Friday
23-10-24	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
23-10-16	Progyny, Inc. : Want to have a baby?
23-09-07	PCAS: Seqens launches minority share offer
23-09-05	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-07-27	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
23-05-31	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
23-05-25	PCAS: sale of Canadian subsidiary confirmed
23-05-25	PCAS to Divest Canadian Arm to Japan's DIC	MT

23-10-24	PCAS: Net Sales as of September 30, 2023	GL
23-09-06	PCAS: RESULTS AS OF JUNE 30, 2023	GL
23-07-27	Pcas: Net sales as of June 30, 2023	GL
23-05-25	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
23-05-02	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

24-02-09	Orapi : l'OPA réouvre le 12 février
24-02-02	Orapi : 3,15 millions d'actions apportées à l'OPA
24-01-05	Progyny, Inc.: ¿Quieres tener un bebé?
23-12-22	Orapi : l'OPA démarre le 27 décembre
23-12-18	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	2025-05-02
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	1999-02-28

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	2014-02-28
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+0.40%	+2.15%	+63.79%	+118.56%	1,055B
JOHNSON & JOHNSON	+0.57%	+1.07%	+49.95%	+73.60%	654B
ABBVIE INC.	+0.69%	+0.76%	+19.42%	+75.03%	467B
ROCHE HOLDING AG	-1.36%	-2.58%	+38.77%	+42.33%	348B
NOVARTIS AG	+1.34%	+4.53%	+22.56%	+29.55%	275B
ASTRAZENECA PLC	-0.48%	-0.54%	+12.66%	+13.50%	258B
AMGEN INC.	+0.23%	+5.80%	+51.83%	+53.60%	224B
GILEAD SCIENCES, INC.	+0.21%	+0.64%	+34.55%	+100.91%	187B
NOVO NORDISK A/S	-0.30%	-2.98%	-28.24%	-61.28%	171B
Average	+0.15%	+0.74%	+29.48%	+49.53%	404.26B
Weighted average by Cap.	+0.26%	+1.32%	+39.92%	+70.09%